Denali Shares Slide 7% After BIIB122 Parkinson’s Trial Misses Endpoints
Denali Therapeutics and Biogen announced that their mid-stage LUMA trial of BIIB122 (DNL151) failed to meet primary and secondary endpoints, leading to a 7% drop in Denali shares. Denali will cease broader idiopathic Parkinson’s development but continue its BEACON study in LRRK2-mutation patients, with results due H1 2027.
1. LUMA Study Results and Share Reaction
The mid-stage LUMA trial of BIIB122 (DNL151) did not achieve its primary or secondary goals for slowing motor and daily-living symptom progression in idiopathic Parkinson’s, despite demonstrating strong target engagement and an acceptable safety profile. Investors reacted negatively, sending Denali Therapeutics shares down approximately 7% in after-hours trading following the announcement.
2. Future Development Strategy
In response to the LUMA trial outcome, Denali and Biogen will halt further development of BIIB122 for the broader idiopathic Parkinson’s population. Denali will maintain its BEACON study focusing on patients with LRRK2 genetic mutations, with topline data expected in the first half of 2027, and will assess the full data package to guide next steps.